Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$RYTM Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.61 up 25.61% YoY • Reported revenue of $92.13M up 79.59% YoY • For 2026, Rhythm Pharmaceuticals anticipates approximately $360M to $380M in Non-GAAP Operating Expenses, including R&D expenses of approximately $165M to $175M and SG&A expenses of approximately $195M to $205M.

Price since post

Full Details

Advertisement|Remove ads.